All articles by Manasi Vaidya

Manasi Vaidya

@manasivaidya22

Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.

Navigating clinical trial operations in the era of collaboration

The upcoming OCT West Coast 2024 conference will feature experts talking about emerging techologies, clinical trial operations for pharma and medical devices, and patient participation in studies.

How to connect patients with rare diseases to clinical trials

Experts say a wider diverse pool of patients needs to be given a chance to participate in clinical research to get rare disease drugs faster to market.

Rare disease drug development needs regulatory incentives to grow in 2024

While orphan drug approvals have hit an all-time high, existing incentives need to continue to further support rare disease research.

Signal- HHS-Regeneron Covid-19 deal includes list price clause for affordability

Regeneron is developing an antibody for Covid-19 prevention with the help of US government funding.

Signal- HHS/Regeneron Covid-19 deal includes list price clause for affordability

Regeneron is developing an antibody for Covid-19 prevention with the help of US government funding.

Signal: Nimbus raises $210m to foster drug discovery plans

Nimbus plans to use these funds to aid new drug discovery efforts and plans to continue existing programs in oncology and metabolic disorder.

Signal: Pharma gears up for IRA-driven drug price negotiation list by CMS

The Centers for Medicare and Medicaid Services will soon release a list of 10 drugs that will be subject to drug price negotiations.

Signal: Gilead targets inflammation and cancer with Tentatrix R&D partnership

Gilead has recently announced early partnerships with biotechs centered on researching protein chemistry and therapeutics for different conditions.

Signal: Top tweets of the week dissect impact of obesity drugs

Ahead of Eli Lilly’s Q2 results, which will likely touch on the company’s plans for obesity drugs, we take a look at the ongoing discourse on this drug class.

Deal focus: Biogen’s gambit to boost neurology portfolio with Reata acquisition

Biogen’s $7.3bn acquisition of Reata gives the company access to the only approved drug for Friedreich’s Ataxia.